Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Celon Pharma.
Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated: “This transaction is an ideal match which furthers the strategic ambitions of both companies. It allows Celon to commercialise the product in the US and provides a perfect addition to Zydus’ respiratory portfolio.”
Mr. Jacek Glinka, Vice President of the Management Board of Celon Pharma, commented: “We are very pleased with the strong and knowledgeable support of Plexus Ventures in all phases of the process leading to this important agreement with Zydus.”
Details of the transaction can be found below in announcement on the Polish Stock exchange issued on December 1, 2022.
Celon Pharma and Zydus Lifesciences Ltd., a global innovation driven healthcare company represented by its wholly subsidiary, Zydus Worldwide DMCC, announced that they have entered into a co-development and commercialization agreement for the combination of salmeterol and fluticasone in dry powder inhaler. The Agreement provides for joint development of a generic product to GSK’s Advair and gives exclusive rights to Zydus for commercialization of the product in the territory of United States of America. The Agreement is for a period of seven years starting from the commercial launch and can be renewed thereafter.
The combination of fluticasone and salmeterol is used to treat the main causes of asthma symptoms which are airway constriction and airway inflammation. The combination therapy is used in adults and children 4 years of age and older.